Prevalence nine times higher for women versus men; rates highest in American Indian/Alaska Natives, Black women
THURSDAY, Jan. 21, 2021 (HealthDay News) — The estimated prevalence of systemic lupus erythematosus (SLE) in the United States is 72.8/100,000, according to a study published online Jan. 21 in Arthritis & Rheumatology.
Peter M. Izmirly, M.D., from the New York University School of Medicine in New York City, and colleagues conducted a meta-analysis estimating the U.S. SLE prevalence using data from the U.S. Centers for Disease Control and Prevention National Lupus Registry network, which includes four registries in unique states and one in the Indian Health Service.
Overall, 5,417 cases fulfilled the 1997 American College of Rheumatology SLE classification criteria. The researchers found that the pooled prevalence was 72.8/100,000 for the four state-specific registries and was nine times higher for women than men (128.7 versus 14.6). Prevalence was highest among Black women, followed by Hispanic, White, and Asian/Pacific Islander women (230.9, 120.7, 84.7, and 84.4, respectively). Among men, prevalence was highest among Blacks, followed by Hispanics, Asian/Pacific Islanders, and Whites (26.7, 18.0, 11.2, and 8.9, respectively). The highest race-specific SLE estimates for women and men were seen for American Indian/Alaska Natives (270.6 and 53.8/100,000, respectively). In the United States, 204,295 persons fulfilled ACR SLE criteria in 2018.
“Our study potentially redefines systemic lupus erythematosus as a rare disease in the United States and lays the groundwork for where we need to focus our efforts to reduce the burden of this disease on Americans,” Izmirly said in a statement.
Two authors disclosed financial ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Few Meet Major Clinical Response Criteria After Treatment Escalation for Lupus
Postoperative Complications Elevated for Patients With Systemic Lupus Erythematosus
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
Low Hydroxychloroquine Intake, Blood Levels Linked to ASCVD Risk in Lupus
Treatment Satisfaction Higher for Patients With RA Choosing Their Own Treatment
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis